Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24.
Article
CAS
PubMed
Google Scholar
Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Pender BS, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019;134(7):636–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles GA, et al. Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). J Clin Oncol. 2020;38(15_suppl):8008-.
Article
Google Scholar
Lemal R, Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J Immunother Cancer. 2019;7(1):202.
Article
PubMed
PubMed Central
Google Scholar
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.
Article
CAS
PubMed
Google Scholar
Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017;25(1):285–95.
Article
CAS
PubMed
PubMed Central
Google Scholar
Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja Js, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Eng J Med. 2021;384(8):705–16.
Article
CAS
Google Scholar
Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119–28.
Article
PubMed
PubMed Central
Google Scholar
Pehlivan KC, Duncan BB, Lee DW. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease. Curr Hematol Malig Rep. 2018;13(5):396–406.
Article
PubMed
Google Scholar
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45–56.
Article
CAS
PubMed
Google Scholar
Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11–22.
Article
CAS
PubMed
Google Scholar
Shah BD, Ghobadi A, Oluwole OO, Logan A, Boissel N, Cassaday RD, et al. Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). J Clin Oncol. 2021;39(15_suppl):7002-.
Article
Google Scholar
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. The Lancet. 2021;398(10299):491–502.
Article
CAS
Google Scholar
Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84.
Article
PubMed
PubMed Central
Google Scholar
Vitale C, Strati P. CAR T-Cell therapy for b-cell non-hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front oncol. 2020;10:849.
Article
PubMed
PubMed Central
Google Scholar
Wang M, Locke FL, Munoz J, Goy A, Holmes HE, Siddiqi T, et al. ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma. J Clin Oncol. 2018;36(15_suppl):TPS3102-TPS.
Article
Google Scholar
Wang M, Munoz J, Goy A, Locke FL, CAJacobson, Hill BT, et al. Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24). J Clin Oncol. 2021;39(15_suppl):7547.
Article
Google Scholar
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang C, Lei W, Xie H, Wu G, Wei J, Liang A, et al. Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4–1BB-Based CD19-Directed CAR-T Therapy. Onco Targets Ther. 2020;13:12163–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
Article
PubMed
PubMed Central
Google Scholar
Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–31.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28.
Article
CAS
PubMed
Google Scholar
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.
Article
PubMed
PubMed Central
Google Scholar
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
FDA. KYMRIAH (tisagenlecleucel): U.S. Food & Drug Administration; 2021 [updated Jun 14, 2021. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel.
FDA. YESCARTA (axicabtagene ciloleucel): U.S. Food & Drug Administration; 2021 [updated May 11, 2021. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel.
FDA. TECARTUS (brexucabtagene autoleucel): U.S. Food & Drug Administration; 2021 [updated Mar 18, 2021. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel.
FDA. ABECMA (idecabtagene vicleucel): U.S. Food & Drug Administration; 2021 [updated Apr 21, 2021. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel.
Guedan S, Calderon H, Posey AD Jr, Maus MV. Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2018;12:145–56.
Article
PubMed
PubMed Central
Google Scholar
Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–98.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials. Molecular Therapy: Methods & Clinical Development. 2020;16:136–44.
CAS
Google Scholar
Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston ICD, et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy. 2016;18(8):1002–11.
Article
CAS
PubMed
Google Scholar
Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ. In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes. Mol Ther. 2020;28(8):1783–94.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pfeiffer A, Thalheimer FB, Hartmann S, Frank AM, Bender RR, Danisch S, et al. In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Mol Med. 2018;10(11):e9158.
Article
PubMed
PubMed Central
Google Scholar
Nawaz W, Huang B, Xu S, Li Y, Zhu L, Yiqiao H, et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 2021;11(6):119.
Article
PubMed
PubMed Central
Google Scholar
Bishop DC, Xu N, Tse B, O’Brien TA, Gottlieb DJ, Dolnikov A, et al. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts. Mol Ther. 2018;26(8):1883–95.
Article
CAS
PubMed
PubMed Central
Google Scholar
ANZCTR. A Phase I Study of CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Persistent and Relapsed B-cell Leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation (CARTELL) (Registry ID: ACTRN12617001579381) Sydney, Australia: National Health and Medical Research Council Australia; 2018 [updated Nov 1, 2018. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373934.
ClinicalTrials.gov. CD19-specific CAR-T Cells in CLL/SLL and DLBCL (Registry ID: NCT03960840): Novartis Pharmaceuticals; 2019 [updated May 14, 2021. Available from: https://ClinicalTrials.gov/show/NCT03960840.
ClinicalTrials.gov. Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia (Registry ID: NCT04289220): Yan'an Affiliated Hospital of Kunming Medical University; 2020 [updated May 13, 2021. Available from: https://ClinicalTrials.gov/show/NCT04289220.
Bishop DC, Clancy LE, Simms R, Burgess J, Mathew G, Moezzi L, Street JA, Sutrave G, Atkins E, McGuire HM, Gloss BS, Lee K, Jiang W, Maddock K, McCaughan G, Avdic S, Antonenas V, O'Brien TA, Shaw PJ, Irving DO, Gottlieb DJ, Blyth E, Micklethwaite KP. Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. Blood. 2021;138(16):1504–9. https://doi.org/10.1182/blood.2021010813.
Micklethwaite KP, Gowrishankar K, Gloss BS, Li Z, Street JA, Moezzi L, Mach MA, Sutrave G, Clancy LE, Bishop DC, Louie RHY, Cai C, Foox J, MacKay M, Sedlazeck FJ, Blombery P, Mason CE, Luciani F, Gottlieb DJ, Blyth E. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021;138(16):1391–405. https://doi.org/10.1182/blood.2021010858.
ClinicalTrials.gov. Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed < 6 Months Post All-HSCT. (ELIANA) (Registry ID: NCT02435849) 2015 [updated June 15, 2021. Available from: https://ClinicalTrials.gov/show/NCT02435849.
Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, et al. Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. Blood. 2018;132(Supplement 1):895.
Article
Google Scholar
Fagnoni FF, Lozza L, Zibera C, Zambelli A, Ponchio L, Gibelli N, et al. T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology. 2002;106(1):27–37.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hakim FT, Cepeda R, Kaimei S, Mackall CL, McAtee N, Zujewski J, et al. Constraints on CD4 Recovery Postchemotherapy in Adults: Thymic Insufficiency and Apoptotic Decline of Expanded Peripheral CD4 Cells. Blood. 1997;90(9):3789–98.
Article
CAS
PubMed
Google Scholar
Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997;89(10):3700–7.
Article
CAS
PubMed
Google Scholar
Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;18(1):10.
Article
PubMed
PubMed Central
Google Scholar
Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in Universal CAR-T Cell Therapy. Front Immunol. 2021;12:744823. https://doi.org/10.3389/fimmu.2021.744823.
Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR Cell Therapy-More Than a Pipe Dream. Front Immunol. 2021;11:618427.
Article
PubMed
PubMed Central
Google Scholar
June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.
Article
CAS
PubMed
Google Scholar
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. “Off-the-shelf” allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99.
Article
CAS
PubMed
Google Scholar
Rivers J, Annesley C, Summers C, Finney O, Pulsipher MA, Wayne AS, et al. Early response data for pediatric patients with Non-Hodgkin Lymphoma treated with CD19 chimeric antigen receptor (CAR) T-Cells. Blood. 2018;132(Supplement 1):2957.
Article
Google Scholar
Costello C, Derman BA, Kocoglu MH, Deol A, Ali AA, Gregory T, et al. Abstract 3858: Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System. American Society of Hematology: 63rd ASH Annual Meeting & Exposition; 2021. https://ash.confex.com/ash/2021/webprogram/Paper151672.html.
Costello CL, Cohen AD, Patel KK, Ali SS, Berdeja JG, Shah N, et al. Abstract 134: Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies. American Society of Hematology: 62rd ASH Annual Meeting & Exposition; 2020. https://ash.confex.com/ash/2020/webprogram/Paper142695.html.
Costello CL, Gregory TK, Ali SA, Berdeja JG, Patel KK, Shah ND, et al. Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME). Blood. 2019;134(Supplement_1):3184.
Article
Google Scholar
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396(10266):1885–94.
Article
CAS
PubMed
Google Scholar
McGuirk J, Bachier CR, Bishop MR, Ho PJ, Murthy HS, Dickinson MJ, et al. A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9-engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON). J Clin Oncol. 2021;39(15_suppl):TPS7570-TPS.
Article
Google Scholar
CRISPR Therapeutics. [Press Release] CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies: Allogene Therapeutics; 2021 [updated Oct 12, 2021. Available from: http://www.crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-reports-positive-results-from-its-phase-1-carbon-trial-of-ctx110-in-relapsed-or-refractory-cd19-b-cell-malignancies.
Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia. 2018;32(11):2307–15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fleischer LC, Spencer HT, Raikar SS. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol. 2019;12(1):141.
Article
PubMed
PubMed Central
Google Scholar
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2019;24(10):1499–503.
Article
Google Scholar
Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541–52.
Article
CAS
PubMed
Google Scholar
Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2016;129(9):1134–42.
Article
Google Scholar
Dogan A, Morice WG. Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol. 2004;127(2):140–54.
Article
PubMed
Google Scholar
Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114(25):5136–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Asnafi V, Beldjord K, Boulanger E, Comba B, Le Tutour P, Estienne MH, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003;101(7):2693–703.
Article
CAS
PubMed
Google Scholar
Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129–39.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther. 2017;25(10):2245–53.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang C, Gao L, Liu Y, Gao L, Kong P-Y, Liu J, et al. Role of donor-derived CD19.CAR-T cells in treating patients that relapsed after allogeneic hematopoietic stem cell transplantation. Blood. 2019;134(Supplement_1):4561.
Article
Google Scholar
Frumento G, Zheng Y, Aubert G, Raeiszadeh M, Lansdorp PM, Moss P, et al. Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity. Am J Transplant. 2013;13(1):45–55.
Article
CAS
PubMed
Google Scholar
Hiwarkar P, Qasim W, Ricciardelli I, Gilmour K, Quezada S, Saudemont A, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. Blood. 2015;126(26):2882–91.
Article
CAS
PubMed
Google Scholar
Yun HD, Varma A, Hussain MJ, Nathan S, Brunstein C. Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation. J Clin Med. 2019;8(11):1968. https://doi.org/10.3390/jcm8111968.
Xu N, Tse B, Yang L, Tang TCY, Haber M, Micklethwaite K, et al. Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy. Immunotargets Ther. 2021;10:123–40.
Article
PubMed
PubMed Central
Google Scholar
Cruz CRY, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase i study. Blood. 2013;122(21):152.
Article
Google Scholar
ClinicalTrials.gov. Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells (Registry ID: NCT01362452): M.D. Anderson Cancer Center; 2017 [updated Aug 3, 2017. Available from: https://ClinicalTrials.gov/show/NCT01362452.
Bleakley M, Turtle CJ, Riddell SR. Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2012;5(4):409–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Klamer G, Shen S, Song E, Rice AM, Knight R, Lindeman R, et al. GSK3 inhibition prevents lethal GVHD in mice. Exp Hematol. 2013;41(1):39-55 e10.
Article
CAS
PubMed
Google Scholar
Wagner JE, Ballen KK, Zhang M-J, Allbee-Johnson M, Karanes C, Milano F, et al. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. 2021. p. 4064–72.
Google Scholar
Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138(3):273–82.
Article
CAS
PubMed
Google Scholar
Anwer F, Shaukat A-A, Zahid U, Husnain M, McBride A, Persky D, et al. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy. 2017;9(2):123–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol. 2016;34(10):1112–21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017;23(2):242–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jin X, Cao Y, Wang L, Sun R, Cheng L, He X, et al. HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation. Leukemia. 2020;34(3):909–13.
Article
PubMed
Google Scholar
Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10(1):35.
Article
PubMed
PubMed Central
Google Scholar
Cruz CRY, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang C, Wang X-Q, Zhang R-L, Liu F, Wang Y, Yan Z-L, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35(6):1563–70.
Article
CAS
PubMed
Google Scholar
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol. 2021;39(30):3340–51.
Article
CAS
PubMed
Google Scholar
Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities. Oncoimmunology. 2017;6(3):e1283460-e.
Article
Google Scholar
Hübner J, Hoseini SS, Suerth JD, Hoffmann D, Maluski M, Herbst J, et al. Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform. Molecular therapy : the journal of the American Society of Gene Therapy. 2016;24(7):1216–26.
Article
Google Scholar
Mohtashami M, Shah DK, Kianizad K, Awong G, Zúñiga-Pflücker JC. Induction of T-cell development by Delta-like 4-expressing fibroblasts. Int Immunol. 2013;25(10):601–11.
Article
CAS
PubMed
Google Scholar
Shen S, Xu N, Symonds G, Dolnikov A. Stem Cell Approach to Generate Cancer Specific Immune Effectors Cells. Int J Stem Cell Res Ther. 2016;3:022.
Article
Google Scholar
Shen S, Xu N, Yang S, O’Brien T, Dolnikov A. Stem Cell Approach to Generate Chimeric Antigen Receptor Modified Immune Effector Cells to Treat Cancer. Cytotherapy. 2016;18(6):S101.
Google Scholar
Kwoczek J, Riese SB, Tischer S, Bak S, Lahrberg J, Oelke M, et al. Cord blood-derived T cells allow the generation of a more naïve tumor-reactive cytotoxic T-cell phenotype. Transfusion. 2017;58(1):88–99.
Article
PubMed
Google Scholar
Bunse M, Bendle GM, Linnemann C, Bies L, Schulz S, Schumacher TN, et al. RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Molecular therapy : the journal of the American Society of Gene Therapy. 2014;22(11):1983–91.
Article
CAS
Google Scholar
ClinicalTrials.gov. A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma (Registry ID: NCT03166878): Chinese PLA General Hospital; 2017 [updated Jun 23, 2017. Available from: https://ClinicalTrials.gov/show/NCT03166878.
ClinicalTrials.gov. Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (Registry ID: NCT04093596): Allogene Therapeutics; 2019 [updated Oct 14, 2021. Available from: https://ClinicalTrials.gov/show/NCT04093596.
ClinicalTrials.gov. Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA) (Registry ID: NCT03939026): Allogene Therapeutics; 2019 [updated Oct 14, 2021. Available from: https://ClinicalTrials.gov/show/NCT03939026.
ClinicalTrials.gov. Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies (Registry ID: NCT04264078) Xinqiao Hospital of Chongqing, Gracell Biotechnology Shanghai Co. Ltd. 2020 [updated Feb 11, 2020. Available from: https://ClinicalTrials.gov/show/NCT04264078.
ClinicalTrials.gov. Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2) (Registry ID: NCT04416984): Allogene Therapeutics; 2020 [updated Oct 14, 2021. Available from: https://ClinicalTrials.gov/show/NCT04416984.
Alarcón B, Gil D, Delgado P, Schamel WW. Initiation of TCR signaling: regulation within CD3 dimers. Immunol Rev. 2003;191(1):38–46.
Article
PubMed
Google Scholar
Call ME, Wucherpfennig KW. Molecular mechanisms for the assembly of the T cell receptor-CD3 complex. Mol Immunol. 2004;40(18):1295–305.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen S, Yang L, Lu X, Li B, Chan JY-H, Cai D, et al. Gene expression profiling of CD3γ, δ, ϵ, and ζ chains in CD4+ and CD8+ T cells from human umbilical cord blood. Hematol. 2010;15(4):230–5.
Article
CAS
Google Scholar
Dietrich J, Neisig A, Hou X, Wegener AM, Gajhede M, Geisler C. Role of CD3 gamma in T cell receptor assembly. J Cell Biol. 1996;132(3):299–310.
Article
CAS
PubMed
Google Scholar
Kuhns MS, Davis MM, Garcia KC. Deconstructing the Form and Function of the TCR/CD3 Complex. Immunity. 2006;24(2):133–9.
Article
CAS
PubMed
Google Scholar
Schatz DG, Ji Y. Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol. 2011;11(4):251–63.
Article
CAS
PubMed
Google Scholar
Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697–705.
Article
CAS
PubMed
PubMed Central
Google Scholar
ClinicalTrials.gov. Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (Registry ID: NCT04613557): Celyad Oncology SA; 2020 [updated Nov 30, 2020. Available from: https://ClinicalTrials.gov/show/NCT04613557.
Anguille S, Al-Homsi AS, Deeren D, Nishihori T, Meuleman N, Abdul-Hay M, et al. Objective response at low dose in the first-in-human IMMUNICY-1 trial evaluating non-gene edited allogeneic CYAD-211 anti-BCMA CAR-T product in relapsed or refractory multiple myeloma. The Hague: EHA2021 Virtual: European Hematology Association; 2021.
Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, et al. Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol Ther. 2016;24(3):570–81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bogdanove AJ, Voytas DF. TAL Effectors: Customizable Proteins for DNA Targeting. Science. 2011;333(6051):1843.
Article
CAS
PubMed
Google Scholar
Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013;14(1):49–55.
Article
CAS
PubMed
Google Scholar
Wah DA, Bitinaite J, Schildkraut I, Aggarwal AK. Structure of FokI has implications for DNA cleavage. Proc Natl Acad Sci USA. 1998;95(18):10564–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lamb BM, Mercer AC, Barbas CF 3rd. Directed evolution of the TALE N-terminal domain for recognition of all 5’ bases. Nucleic Acids Res. 2013;41(21):9779–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
ClinicalTrials.gov. Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL) (Registry ID: NCT02808442): Institut de Recherches Internationales Servier; 2020 [updated Dec 24, 2020. Available from: https://ClinicalTrials.gov/show/NCT02808442.
Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):eaaj2013. https://doi.org/10.1126/scitranslmed.aaj2013.
Levitsky J, Leventhal JR, Miller J, Huang X, Chen L, Chandrasekaran D, et al. Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Hum Immunol. 2012;73(2):141–9.
Article
CAS
PubMed
Google Scholar
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science. 2013;339(6121):819.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci. 2012;109(39):E2579.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012;337(6096):816.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24(7):939–46.
Article
CAS
PubMed
Google Scholar
Amatya C, Pegues MA, Lam N, Vanasse D, Geldres C, Choi S, et al. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. Mol Ther. 2021;29(2):702–17.
Article
CAS
PubMed
Google Scholar
Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, et al. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Mol Ther. 2017;25(3):580–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Duong MT, Collinson-Pautz MR, Morschl E, Lu A, Szymanski SP, Zhang M, et al. Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches. Mol Ther Oncol. 2019;12:124–37.
Article
Google Scholar
Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149–57.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420–4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nianias A, Themeli M. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges. Curr Hematol Malig Rep. 2019;14(4):261–8.
Article
PubMed
PubMed Central
Google Scholar
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol. 2021;39(30):3340–51.
Wang X, Li S, Gao L, Yuan Z, Wu K, Liu L, et al. Abstract CT052: Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). Cancer Res. 2020;80(16 Supplement):CT052.
Article
Google Scholar
Li S, Gao L, Yuan Z, Wu K, Liu L, Luo L, et al. Abstract LB147: Updates on clinical safety and efficacy result of GC027, the first-in-human, “Off-the-Shelf” CD7 CAR-T stand-alone therapy for adult patients with relapsed/refractory T-cell lymphoblastic leukemia (r/r T-ALL). Cancer Res. 2021;81(13 Supplement):LB147-LB.
Article
Google Scholar
Georgiadis C, Rasaiyaah J, Gkazi SA, Preece R, Etuk A, Christi A, Qasim W. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. 2021;35(12):3466–81. https://doi.org/10.1038/s41375-021-01282-6.
ClinicalTrials.gov. NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (Registry ID: NCT03399448): University of Pennsylvania, Parker Institute for Cancer Immunotherapy, Tmunity Therapeutics; 2018 [updated Oct 12, 2020. Available from: https://ClinicalTrials.gov/show/NCT03399448.
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. https://doi.org/10.1126/science.aba7365.
Lanza F, Maffini E, Rondoni M, Massari E, Faini AC, Malavasi F. CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults. Cancers. 2020;12(2):303.
Article
CAS
PubMed Central
Google Scholar
Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, et al. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2021;27(10):2764.
Article
CAS
PubMed
Google Scholar
Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kagoya Y, Guo T, Yeung B, Saso K, Anczurowski M, Wang CH, Murata K, Sugata K, Saijo H, Matsunaga Y, Ohashi Y, Butler MO, Hirano N. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy. Cancer Immunol Res. 2020;8(7):926–36. https://doi.org/10.1158/2326-6066.CIR-18-0508.
Kamiya T, Wong D, Png YT, Campana D. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv. 2018;2(5):517–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stenger D, Stief TA, Käuferle T, Willier S, Rataj F, Schober K, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood. 2020.
Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559(7714):405–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
ClinicalTrials.gov. Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (IGNITE) (Registry ID: NCT05000450): Allogene Therapeutics; 2021 [updated Oct 14, 2021. Available from: https://ClinicalTrials.gov/show/NCT05000450.
ClinicalTrials.gov. Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (Registry ID: NCT04696731) (TRAVERSE): Allogene Therapeutics; 2021 [updated Oct 14, 2021. Available from: https://ClinicalTrials.gov/show/NCT04696731.
Allogene. [Press Release] Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial: Allogene Therapeutics; 2021 [updated Oct 7, 2021. Available from: https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-fda-clinical-hold-allocar-t-trials.
Allogene. [Press Release] Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update: Allogene Therapeutics; 2021 [updated Nov 4, 2021. Available from: https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-third-quarter-2021-financial.
Allogene. [Press Release] Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials: Allogene Therapeutics; 2021 [updated Jan 10, 2022. Available from: https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-announces-removal-fda-clinical-hold-across.